The expanding role of marine microbes in pharmaceutical development

Newman, 2007, Natural products as sources of new drugs over the last 25 years, J Nat Prod, 70, 461, 10.1021/np068054v

Blunt, 2007, Marine natural products, Nat Prod Rep, 24, 31, 10.1039/b603047p

Mayer, 2010, The odyssey of marine pharmaceuticals: a current pipeline perspective, Trends Pharmacol Sci, 31, 255, 10.1016/j.tips.2010.02.005

Piel, 2009, Metabolites from symbiotic bacteria, Nat Prod Rep, 26, 338, 10.1039/B703499G

Gulder, 2009, Chasing the treasures of the sea—bacterial marine natural products, Curr Opin Microbiol, 12, 252, 10.1016/j.mib.2009.05.002

Schmidt, 2010, Life in cellulose houses: symbiotic bacterial biosynthesis of ascidian drugs and drug leads, Curr Opin Biotechnol, 10.1016/j.copbio.2010.10.006

Trindade-Silva, 2010, Bryostatins: biological context and biotechnological prospects, Curr Opin Biotechnol, 10.1016/j.copbio.2010.09.018

Kobayashi, 1997, Antitumor activity of TZT-1027, a novel dolastatin 10 derivative, Jpn J Cancer Res, 88, 316, 10.1111/j.1349-7006.1997.tb00383.x

Ebbinghaus, 2005, A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors, Clin Cancer Res, 11, 7807, 10.1158/1078-0432.CCR-05-0909

Pettit, 1981, Marine animal biosynthetic constituents for cancer chemotherapy, J Nat Prod, 44, 482, 10.1021/np50016a016

Luesch, 2001, Isolation, of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1, J Nat Prod, 64, 610, 10.1021/np010049y

Harrigan, 1998, Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages, J Nat Prod, 61, 1221, 10.1021/np9801211

Feling, 2003, Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora, Angew Chem Int Ed Engl, 42, 355, 10.1002/anie.200390115

Davidson, 2001, Evidence for the biosynthesis of bryostatins by the bacterial symbiont “Candidatus Endobugula sertula” of the bryozoan Bugula neritina, Appl Environ Microbiol, 67, 4531, 10.1128/AEM.67.10.4531-4537.2001

Yamazaki, 2010, Anti-microtubule ‘plinabulin’ chemical probe KPU-244-B3 labeled both alpha- and beta-tubulin, Bioorg Med Chem, 18, 3169, 10.1016/j.bmc.2010.03.037

Fenical WDM, Jensen PR, Cheng XC: Halimide, a cytotoxic marine natural product, and derivatives thereof. US 6069146 A. Publ. 5/30/2000.

Kanoh, 1999, Antitumor activity of phenylahistin in vitro and in vivo, Biosci Biotechnol Biochem, 63, 1130, 10.1271/bbb.63.1130

Cuevas, 2009, Development of Yondelis (trabectedin, ET-743): a semisynthetic process solves the supply problem, Nat Prod Rep, 26, 322, 10.1039/b808331m

Ocio, 2009, Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks, Blood, 113, 3781, 10.1182/blood-2008-09-177774

Mikami, 1985, Biosynthetic studies on saframycin A, a quinone antitumor antibiotic produced by Streptomyces lavendulae, J Biol Chem, 260, 344, 10.1016/S0021-9258(18)89738-1

Cuevas, 2000, Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B, Org Lett, 2, 2545, 10.1021/ol0062502

Newman, 2007, Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer, Curr Opin Investig Drugs, 8, 1057

Demydchuk, 2008, Analysis of the tetronomycin gene cluster: insights into the biosynthesis of a polyether tetronate antibiotic, Chembiochem, 9, 1136, 10.1002/cbic.200700715

Harvey, 2007, Insights into polyether biosynthesis from analysis of the nigericin biosynthetic gene cluster in Streptomyces sp. DSM4137, Chem Biol, 14, 703, 10.1016/j.chembiol.2007.05.011

Hoshi, 2000, Microbial and chemical conversion of antibiotic K41. II. Preparation of K41-DA1-DA2 and -DA3 deamicetosyl derivatives of antibiotic K41, J Antibiot (Tokyo), 53, 1154, 10.7164/antibiotics.53.1154

Beer, 2007, Biosynthetic convergence of salinosporamides A and B in the marine actinomycete Salinispora tropica, Org Lett, 9, 845, 10.1021/ol063102o

Sudek, 2007, Identification of the putative bryostatin polyketide synthase gene cluster from “Candidatus Endobugula sertula”, the uncultivated microbial symbiont of the marine bryozoan Bugula neritina, J Nat Prod, 70, 67, 10.1021/np060361d

Hill RT, Hamann MT, Enticknap J, Rao KV, Fuierer M: Kahalalide-Producing Bacteria. WO 2005/042720 A3. Publ. 5/12/2005

Hamann, 2007, The manzamines as an example of the unique structural classes available for the discovery and optimization of infectious disease controls based on marine natural products, Curr Pharm Des, 13, 653, 10.2174/138161207780162818

Rao, 2006, Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical parasitic, and Alzheimer's diseases, J Nat Prod, 69, 1034, 10.1021/np0601399

Peng, 2010, Structure–activity relationship and mechanism of action studies of manzamine analogues for the control of neuroinflammation and cerebral infections, J Med Chem, 53, 61, 10.1021/jm900672t

Hill RT, Hamann MT, Peraud O, Kasanah N: Manzamine Producing Actinomycetes. WO 2004/013297A3. Publ. 2/12/2004

Baldwin, 1992, Biosyntheis of manzamines, Tetrahedron Lett, 33, 2059, 10.1016/0040-4039(92)88141-Q

Adolf, 2009, Environmental modulation of karlotoxin levels in strains of the cosmopolitan dinoflagellate, Karlodinium veneficum (Dinophyceae), J Phycol, 45, 176, 10.1111/j.1529-8817.2008.00641.x

Wang, 2008, Neurotoxins from marine dinoflagellates: a brief review, Mar Drugs, 6, 349, 10.3390/md6020349

Peng, 2007, Marine microbes: the critical role they play in sustainable production of starting materials for the synthesis of drug leads and the structure for the elusive Pfiesteria-associated fish killing toxin using 13C enrichment and dual cryoprobe NMR studies

Bachvaroff, 2008, Characterization and quantification of karlotoxins by liquid chromatography–mass spectrometry, Harmful Algae, 7, 473, 10.1016/j.hal.2007.10.003

Place AR, Deeds JR: Dinoflagellate Karlotoxins, Methods of Isolation and Uses Thereof. WO 2004/100659 A2. Publ. 11/25/2004.

Peng, 2010, Structure and absolute configuration of karlotoxin-2, an ichthyotoxin from the marine dinoflagellate Karlodinium veneficum, J Am Chem Soc, 132, 3277, 10.1021/ja9091853

Van Wagoner, 2008, Isolation and characterization of karlotoxin 1, a new amphipathic toxin from Karlodimiun veneficum, Tetrahedron Lett, 49, 6457, 10.1016/j.tetlet.2008.08.103

Sheng, 2010, A dinoflagellate exploits toxins to immobilize prey prior to ingestion, Proc Natl Acad Sci, 107, 2082, 10.1073/pnas.0912254107

Place, 2009, Dinoflagellate host-parasite sterol profiles dictate karlotoxin sensitivity, J Phycol, 45, 375, 10.1111/j.1529-8817.2009.00649.x

Berg, 2002, The Biosynthesis of Membrane Lipids and Steroids

American Heart Association: Cholesterol. [cited 2010; available from http://www.americanheart.org/presenter.jhtml?identifier=4488].

Ablan, 2006, The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion, Virol J, 3, 104, 10.1186/1743-422X-3-104

Luo, 2008, The functional roles of lipid rafts in T cell activation, immune diseases and HIV infection and prevention, Cell Mol Immunol, 5, 1, 10.1038/cmi.2008.1

Fantini, 2002, Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases, Expert Rev Mol Med, 20

Fantini, 2009, Sphingolipid/cholesterol regulation of neurotransmitter receptor conformation and function, Biochim Biophys Acta, 1788, 2345, 10.1016/j.bbamem.2009.08.016

Agargun, 2004, Serum lipid concentrations in obsessive-compulsive disorder patients with and without panic attacks, Can J Psychiatry, 49, 776, 10.1177/070674370404901109

Pandey, 2008, Mycobacterial persistence requires the utilization of host cholesterol, Proc Natl Acad Sci, 105, 4376, 10.1073/pnas.0711159105

Alchorn A: Lipid rafts observed in cell membranes. Sci Tech Rev 2007, 9 [cited 2010; available from https://www.llnl.gov/str/May07/Ratto.html].

Simons, 2002, Cholesterol, lipid rafts and disease, J Clin Invest, 110, 597, 10.1172/JCI0216390

Li, 2006, Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents, Am J Pathol, 168, 1107, 10.2353/ajpath.2006.050959

Solomon, 2009, Ezetimibe is an inhibitor of tumor angiogenesis, Am J Pathol, 174, 1017, 10.2353/ajpath.2009.080551